Correlation between zoledronic acid infusion and repeat vertebroplasty surgery in osteoporotic patients

References

• Cummings SR, Kelsey JL, Nevitt MC, O’Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemio Epidemiol Rev 1985;7:178-208
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly iv infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010;25:2239-50
   PubMed Web of Science ®Google Scholar
• Binkley N. Osteoporosis in men. Arq Bras Endocrinol Metabol 2006;50:764-74
   PubMedGoogle Scholar
• Kamel HK. Male osteoporosis: new trends in diagnosis and therapy. Drugs Aging 2005;22:741-8
   PubMed Web of Science ®Google Scholar
• Colón-Emeric C, Nordsletten L, Olson S, et al. Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 2011;22:2329-36
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128:793-800
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
   PubMed Web of Science ®Google Scholar
• Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3
   PubMed Web of Science ®Google Scholar
• Kotowicz MA, Melton LJ III, Cooper C, et al. Risk of hip fracture in women with vertebral fracture. J Bone Miner Res 1994;9:599-605
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141-51
   PubMed Web of Science ®Google Scholar
• Cramer JA, Lynch NO, Gaudin AF, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006;28:1686-94
   PubMed Web of Science ®Google Scholar
• Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int 2007;18:711-19
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
   PubMed Web of Science ®Google Scholar
• Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253-63
   PubMed Web of Science ®Google Scholar
• Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61
   PubMed Web of Science ®Google Scholar
• Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012;367:1714-23
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809
   PubMed Web of Science ®Google Scholar
• Li C, Wang HR, Li XL, et al. The relation between zoledronic acid infusion and interbody fusion in patients undergoing transforaminal lumbar interbody fusion surgery. Acta Neurochir (Wien) 2012;154:731-8
   PubMed Web of Science ®Google Scholar
• Lee ST, Chen JF. A syringe compressor for vertebroplasty: technical note. Surg Neurol 2004;61:580-4
   PubMedGoogle Scholar
• Anderson PA, Froyshteter AB, Tontz WL Jr. Meta-analysis of vertebral augmentation compared with conservative treatment for osteoporotic spinal fractures. J Bone Miner Res 2013;28:372-82
   PubMed Web of Science ®Google Scholar
• Belkoff SM, Mathis JM, Fenton DC, et al. An ex vivo biomechanical evaluation of an inflatable bone tamp used in the treatment of compression fracture. Spine 2001;26:151-6
   PubMed Web of Science ®Google Scholar
• Polikeit A, Nolte LP, Ferguson SJ. The effect of cement augmentation on the load transfer in an osteoporotic functional spinal unit: finite-element analysis. Spine 2003;28:991-6
   PubMed Web of Science ®Google Scholar
• Villarraga ML, Bellezza AJ, Harrigan TP, et al. The biomechanical effects of kyphoplasty on treated and adjacent nontreated vertebral bodies. J Spinal Disord Tech 2005;18:84-91
   PubMed Web of Science ®Google Scholar
• Klazen CA, Lohle PN, de Vries J, et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. Lancet 2010;376:1085-92
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Parker SL, Wolinsky JP, et al. Vertebroplasty and kyphoplasty for the treatment of vertebral compression fractures: an evidenced-based review of the literature. Spine J 2009;9:501-8
   PubMed Web of Science ®Google Scholar
• Masala S, Ciarrapico AM, Konda D, et al. Cost-effectiveness of percutaneous vertebroplasty in osteoporotic vertebral fractures. Eur Spine J 2008;17:1242-50
   PubMed Web of Science ®Google Scholar
• Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med 2009;361:557-68
   PubMed Web of Science ®Google Scholar